Jennifer Figueroa
Family · Ormond Beach, FLNPI 1013642149
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 345 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,518, 6.0 times the $590 reported in 2023. Among family clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 345 payments — averaging $20.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$968
- AstraZeneca$883
- Pfizer$583
- Amgen$435
- Boehringer Ingelheim$362
- plus $3K from 30 others
What the payments were for
- Food & beverage$7,119100%
- Education$350%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 49 | $1,048 |
| AbbVie | 51 | $968 |
| AstraZeneca | 33 | $883 |
| Pfizer | 32 | $583 |
| Amgen | 23 | $435 |
| Boehringer Ingelheim | 20 | $362 |
| Lilly USA, LLC | 17 | $306 |
| Vanda Pharmaceuticals Inc. | 15 | $304 |
| Axsome Therapeutics, Inc. | 9 | $270 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $212 |
| Lundbeck LLC | 8 | $208 |
| Bayer | 7 | $163 |
| Exact Sciences | 9 | $162 |
| GSK | 8 | $134 |
| Renalytix AI, Inc. | 6 | $110 |
| Scilex Pharmaceuticals Inc. | 6 | $101 |
| Daiichi Sankyo Inc. | 4 | $97 |
| Abbott | 4 | $81 |
| Johnson & Johnson | 4 | $80 |
| Evoke Pharma, Inc. | 4 | $75 |
| Alk-abello, Inc | 3 | $72 |
| Otsuka America Pharmaceutical, Inc. | 3 | $71 |
| Merck | 3 | $52 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| Verona Pharma, Inc. | 2 | $40 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| Idorsia Pharmaceuticals US Inc | 2 | $37 |
| Celltrion USA Inc. | 2 | $35 |
| Eisai Inc. | 1 | $34 |
| Impel Pharmaceuticals LLC | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 1 | $30 |
| Sanofi | 1 | $22 |
| Photonicare Inc | 1 | $22 |
| Dexcom, Inc. | 1 | $15 |
| Acadia Pharmaceuticals Inc | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,154 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx (2 Syringes)Secukinumab | 13 | $111,226 |
| OtezlaApremilast | 16 | $91,268 |
| FarxigaDapagliflozin Propanediol | 48 | $43,730 |
| MounjaroTirzepatide | 32 | $42,857 |
| OzempicSemaglutide | 17 | $27,339 |
| EliquisApixaban | 22 | $25,494 |
| JardianceEmpagliflozin | 24 | $24,240 |
| VraylarCariprazine Hcl | 13 | $18,909 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $6,786 |
| Aripiprazole OdtAripiprazole | 11 | $1,746 |
| Gabapentin | 72 | $1,667 |
| SynthroidLevothyroxine Sodium | 20 | $1,346 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 69 | $1,210 |
| Hydroxyzine Hcl | 29 | $1,047 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 21 | $866 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $435 | $91,26816 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $883 | $50,51659 claims |
| Lilly USA, LLCMounjaro | $306 | $42,85732 claims |
| Novo NordiskOzempic | $1,048 | $27,33917 claims |
| PfizerEliquis | $583 | $25,49422 claims |
| Boehringer IngelheimJardiance | $362 | $24,24024 claims |
| AbbVieVraylar, Synthroid | $968 | $20,25533 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Ormond Beach
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
- Ronda CrewsJax Bch$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.